[go: up one dir, main page]

MXPA04005157A - Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal. - Google Patents

Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.

Info

Publication number
MXPA04005157A
MXPA04005157A MXPA04005157A MXPA04005157A MXPA04005157A MX PA04005157 A MXPA04005157 A MX PA04005157A MX PA04005157 A MXPA04005157 A MX PA04005157A MX PA04005157 A MXPA04005157 A MX PA04005157A MX PA04005157 A MXPA04005157 A MX PA04005157A
Authority
MX
Mexico
Prior art keywords
processes
cell growth
abnormal cell
preparation
treatment
Prior art date
Application number
MXPA04005157A
Other languages
English (en)
Inventor
David Harold Brown Ripin
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA04005157A publication Critical patent/MXPA04005157A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invencion se refiere a procedimientos para preparar compuestos de formula 1(ver formula 1)y sales, profarmacos y solvatos farmaceuticamente aceptables de los mismos, en donde R1, R3, R4, R5, R11, m y p son como se han definido en este documento; los compuestos de formula 1 son utiles en el tratamiento del crecimiento celular anormal en mamiferos por la administracion de composiciones farmaceuticas.
MXPA04005157A 2001-11-30 2002-10-03 Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal. MXPA04005157A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33464701P 2001-11-30 2001-11-30
PCT/IB2002/004097 WO2003045939A1 (en) 2001-11-30 2002-10-03 Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
MXPA04005157A true MXPA04005157A (es) 2004-08-11

Family

ID=23308141

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005157A MXPA04005157A (es) 2001-11-30 2002-10-03 Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.

Country Status (28)

Country Link
US (1) US20030144506A1 (es)
EP (1) EP1448551B1 (es)
JP (1) JP4220388B2 (es)
KR (1) KR20040054813A (es)
CN (1) CN1639149A (es)
AR (1) AR037591A1 (es)
AT (1) ATE377009T1 (es)
AU (1) AU2002337428A1 (es)
BR (1) BR0214606A (es)
CA (1) CA2462149C (es)
DE (1) DE60223279T2 (es)
DO (1) DOP2002000519A (es)
ES (1) ES2295409T3 (es)
GT (1) GT200200245A (es)
HN (1) HN2002000334A (es)
HU (1) HUP0500117A3 (es)
IL (1) IL160971A0 (es)
MX (1) MXPA04005157A (es)
PA (1) PA8558601A1 (es)
PE (1) PE20030643A1 (es)
PL (1) PL370911A1 (es)
RS (1) RS44004A (es)
RU (1) RU2004116345A (es)
SV (1) SV2004001419A (es)
TN (1) TNSN02096A1 (es)
TW (1) TW200300691A (es)
WO (1) WO2003045939A1 (es)
ZA (1) ZA200402054B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006513179A (ja) * 2002-12-18 2006-04-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のための4−アニリノキナゾリン誘導体
PL377533A1 (pl) * 2002-12-19 2006-02-06 Pfizer Products Inc. Kompleksy E-2-metoksy-N-(3-{4-[3-metylo-4-(6-metylopirydyn-3-yloksy)-fenyloamino]-chinazolin-6-ylo}-allilo)-acetamidu, sposób ich wytwarzania i zastosowanie
WO2004089934A1 (en) * 2003-04-09 2004-10-21 Pfizer Products Inc. Processes for the preparation of n-((((pyridinyloxy) -phenylamino) quinazolinyl)- allyl) acetamide derivatives and related compounds as well as intermediates of such processes and processes for the preparation of such intermediates
US7618975B2 (en) * 2003-07-03 2009-11-17 Myriad Pharmaceuticals, Inc. 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
MXPA06012756A (es) * 2004-05-06 2007-01-16 Warner Lambert Co 4-fenilamino-quinazolin-6-il-amidas.
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US20090155509A1 (en) * 2005-12-02 2009-06-18 Suresh Vedprakash Gupta Holographic Flexible Tube Laminate For Packaging and Method of Making the Same
KR20210137422A (ko) 2018-09-25 2021-11-17 블랙 다이아몬드 테라퓨틱스, 인코포레이티드 티로신 키나아제 억제제로서의 퀴나졸린 유도체, 조성물, 이들의 제조 방법 및 이들의 용도
KR102910319B1 (ko) 2019-08-15 2026-01-09 블랙 다이아몬드 테라퓨틱스, 인코포레이티드 알키닐 퀴나졸린 화합물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (es) * 1994-11-12 1997-12-01 Zeneca Ltd
DE19501481A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,8-Disubstituierte Chinazolinone
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
EA005525B1 (ru) * 2000-06-22 2005-04-28 Пфайзер Продактс Инк. Замещенные бициклические производные для лечения аномального роста клеток

Also Published As

Publication number Publication date
JP2005515986A (ja) 2005-06-02
ATE377009T1 (de) 2007-11-15
HN2002000334A (es) 2003-02-21
ES2295409T3 (es) 2008-04-16
PL370911A1 (en) 2005-05-30
DE60223279D1 (de) 2007-12-13
RU2004116345A (ru) 2005-03-27
DOP2002000519A (es) 2003-05-31
KR20040054813A (ko) 2004-06-25
CA2462149C (en) 2010-06-22
CA2462149A1 (en) 2003-06-05
PA8558601A1 (es) 2003-06-30
ZA200402054B (en) 2005-05-23
CN1639149A (zh) 2005-07-13
JP4220388B2 (ja) 2009-02-04
GT200200245A (es) 2003-09-24
PE20030643A1 (es) 2003-07-23
IL160971A0 (en) 2004-08-31
AR037591A1 (es) 2004-11-17
HUP0500117A2 (hu) 2005-05-30
HUP0500117A3 (en) 2008-03-28
US20030144506A1 (en) 2003-07-31
DE60223279T2 (de) 2008-05-29
RS44004A (sr) 2006-10-27
AU2002337428A1 (en) 2003-06-10
BR0214606A (pt) 2004-09-14
TNSN02096A1 (en) 2005-12-23
TW200300691A (en) 2003-06-16
EP1448551B1 (en) 2007-10-31
WO2003045939A1 (en) 2003-06-05
EP1448551A1 (en) 2004-08-25
SV2004001419A (es) 2004-02-24

Similar Documents

Publication Publication Date Title
YU95102A (sh) Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija
MXPA05006420A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal.
MY124390A (en) Substituted bicyclic derivatives useful as anticancer agents
YU30702A (sh) Novi derivati benzoimidazola, korisni agensi protiv proliferacije
MY139357A (en) Novel benzoimidazole derivatives useful as antiproliferative agents
DE69923849D1 (de) Quinolin-2-on-derivate verwendbar als antikrebsmittel
ATE260263T1 (de) Heteroaromatische bizyklische verbindungen mit antikrebswirkung
AP2001002079A0 (en) Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents.
MXPA04000577A (es) Derivados de dolastatina 10.
BG104998A (en) Isothiazole derivatives useful as anticancer agents
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
MX2007004183A (es) Derivados de benzoimidazol utiles como agentes antiproliferacion.
MXPA04005157A (es) Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
DE69734678D1 (de) 6-0-substitutierte eryththromycin-verbindungen und verfahrenen zu ihrer herstellung
WO2006129168A3 (en) Bicyclic derivatives for the treatment of abnormal cell growth
AP2002002494A0 (en) Hygromycin derivatives.
AP2002002492A0 (en) Hygromycin a prodrugs.
UY26785A1 (es) Derivados bicíclicos sustituidos para el tratamiento del crecimiento celular anormal

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights